176 related articles for article (PubMed ID: 36585536)
1. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma.
Anteby R; Blaszkowsky LS; Hong TS; Qadan M
Ann Surg Oncol; 2023 Apr; 30(4):2473-2481. PubMed ID: 36585536
[TBL] [Abstract][Full Text] [Related]
2. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
[TBL] [Abstract][Full Text] [Related]
3. The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases.
Altman AM; White MJ; Marmor S; Shukla D; Chang K; Lou E; LaRocca CJ; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Cancer Control; 2022; 29():10732748221109991. PubMed ID: 35839251
[TBL] [Abstract][Full Text] [Related]
4. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
5. National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection.
Ellis RJ; Ho JW; Schlick CJR; Merkow RP; Bentrem DJ; Bilimoria KY; Yang AD
Ann Surg Oncol; 2020 Mar; 27(3):909-918. PubMed ID: 31691112
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
8. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.
Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044
[TBL] [Abstract][Full Text] [Related]
9. Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer.
Hao S; Mitsakos A; Irish W; Tuttle-Newhall JE; Parikh AA; Snyder RA
J Surg Oncol; 2022 Aug; 126(2):302-313. PubMed ID: 35315932
[TBL] [Abstract][Full Text] [Related]
10. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
Sugawara T; Rodriguez Franco S; Sherman S; Kirsch MJ; Colborn K; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
JAMA Oncol; 2023 Mar; 9(3):316-323. PubMed ID: 36480190
[TBL] [Abstract][Full Text] [Related]
11. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database.
Hamad A; Underhill J; Ansari A; Thayaparan V; Cloyd JM; Li Y; Pawlik TM; Tsung A; Abushahin L; Ejaz A
Surgery; 2022 Jun; 171(6):1464-1470. PubMed ID: 35115154
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
[TBL] [Abstract][Full Text] [Related]
13. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
14. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
15. In search of lost time: Delays in adjuvant therapy for pancreatic adenocarcinoma among under-resourced patient populations.
Hamad A; Eskander MF; Shen C; Bhattacharyya O; Fisher JL; Oppong BA; Obeng-Gyasi S; Tsung A
Surgery; 2022 Sep; 172(3):982-988. PubMed ID: 35595567
[TBL] [Abstract][Full Text] [Related]
16. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma.
Sanford NN; Aguilera TA; Folkert MR; Ahn C; Mahal BA; Zeh H; Beg MS; Mansour J; Sher DJ
J Natl Compr Canc Netw; 2019 Nov; 17(11):1292-1300. PubMed ID: 31693987
[TBL] [Abstract][Full Text] [Related]
17. Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma.
Wright MJ; Overton HN; Teinor JA; Ding D; Burkhart RA; Cameron JL; He J; Wolfgang CL; Weiss MJ; Javed AA
J Gastrointest Surg; 2020 Jul; 24(7):1590-1596. PubMed ID: 31270718
[TBL] [Abstract][Full Text] [Related]
18. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
[TBL] [Abstract][Full Text] [Related]
19. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
20. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis.
Mackay TM; Smits FJ; Roos D; Bonsing BA; Bosscha K; Busch OR; Creemers GJ; van Dam RM; van Eijck CHJ; Gerhards MF; de Groot JWB; Groot Koerkamp B; Haj Mohammad N; van der Harst E; de Hingh IHJT; Homs MYV; Kazemier G; Liem MSL; de Meijer VE; Molenaar IQ; Nieuwenhuijs VB; van Santvoort HC; van der Schelling GP; Stommel MWJ; Ten Tije AJ; de Vos-Geelen J; Wit F; Wilmink JW; van Laarhoven HWM; Besselink MG;
HPB (Oxford); 2020 Feb; 22(2):233-240. PubMed ID: 31439478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
